

**Mo-99 2015 TOPICAL MEETING ON  
MOLYBDENUM-99 TECHNOLOGICAL DEVELOPMENT**

**AUGUST 31-SEPTEMBER 3, 2015  
HILTON BOSTON BACK BAY  
BOSTON, MASSACHUSETTS**

**Title: UPPI LEU Walk: The Difficulty Intersecting Strategies Pose in  
the Transition to non-HEU Medical Radiopharmaceuticals**

John Witkowski  
President

UPPI, LLC. 5400 Laurel Springs Parkway Suite 405 Suwanee, Georgia 30024, USA.

**ABSTRACT**

The radiopharmacy network of UPPI is 'actionable' to place and promote the transition of radiopharmaceuticals manufactured from HEU sources to those by non-HEU (or LEU) production methods. Beyond the important role in delivering patient doses of non-HEU radiopharmaceuticals to the molecular imaging community, UPPI via its LEU Walk has developed solutions to difficulties which arose from parallel strategies of Mo 99 stakeholders and those who should become stakeholders. Key to being actionable is the development of broader solutions that keep the transition moving forward. Challenges are presented when working with Hospital Group Purchasing Organizations, Hospital Supply Chain, material management and others interested parties in understanding the impact that the principle of Full Cost Recovery will have on the market space.